MedTrace Logo

A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

NCT00703742 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2019-09-17

No results posted yet for this study

Summary

The purpose of this study is:

1. to find out the structural or functional effects of selective serotonin reuptake inhibitors (SSRI) in major depressive disorder (MDD);
2. find special abnormalities in depression secondary to other disease, e.g., autoimmune disease like systemic lupus erythematosus (SLE).
3. find the relationship between the efficacy of antidepressant and the change of neuroimaging in MDD
4. to find possible predispose to MDD
5. to explore the DNA methylation status in depression;

Conditions

  • Depression
  • Depression Secondary to Other Disease

Interventions

DRUG

Escitalopram

A,1: Escitalopram, oral, 20 mg/day, 8 weeks

Sponsors & Collaborators

  • Chinese Academy of Sciences

    collaborator OTHER_GOV

  • Kunming Medical University

    lead OTHER

Principal Investigators

  • Xu Xiufeng · Kunming Medical University

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00703742 on ClinicalTrials.gov